vorinostat has been researched along with Cancer of Pelvis in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat was administered orally once daily, 3 h before each radiotherapy fraction, at the following dose levels: 100 mg (n=1), 200 mg (n=4), 300 mg (n=6), and 400 mg (n=6)." | 2.75 | Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study. ( Abrahamsen, TW; Dueland, S; Flatmark, K; Folkvord, S; Hole, KH; Johansen, M; Ree, AH; Seierstad, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ree, AH | 2 |
| Saelen, MG | 1 |
| Kalanxhi, E | 1 |
| Østensen, IH | 1 |
| Schee, K | 1 |
| Røe, K | 1 |
| Abrahamsen, TW | 2 |
| Dueland, S | 2 |
| Flatmark, K | 2 |
| Folkvord, S | 1 |
| Hole, KH | 1 |
| Seierstad, T | 1 |
| Johansen, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study on Suberoylanilide Hydroxyamic Acid (Vorinostat) a Histone Deacetylase Inhibitor, in Palliative Radiotherapy for Advanced Tumors.[NCT00455351] | Phase 1 | 15 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for vorinostat and Cancer of Pelvis
| Article | Year |
|---|---|
Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.
Topics: Aged; Aged, 80 and over; Animals; Biomarkers; Combined Modality Therapy; Disease Models, Animal; Fem | 2014 |
Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.
Topics: Aged; Aged, 80 and over; Colonic Neoplasms; Combined Modality Therapy; Dose-Response Relationship, D | 2010 |